Ellen C. Dompeling

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois et al. · The Lancet Oncology · 2022 · 58 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis

Jasper A. Remijn, Martin J. W. IJsseldijk, Annuska Strunk et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2007 · 55 citations

Medicine, Hematology, Pharmacology +14

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht et al. · Blood · 2023 · 40 citations · Full text

Medicine, Hematology, Oncology +7

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial

Sabina Kersting, Julie Dubois, Kazem Nasserinejad et al. · The Lancet Haematology · 2022 · 31 citations · Full text

Medicine, Hematology, Pharmacology +3

Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

Lina van der Straten, Claudia A.M. Stege, Sabina Kersting et al. · Blood · 2023 · 28 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +6